DrugBiological
Palivizumab clinical trials
Also written Synagis.
- studies test it
- 10
- open now
- 0
- in phase 3
- 5
- first study started
- 1999
How studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 1999 (1)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 5
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
MedImmune LLC (3) · AstraZeneca (1) · mAbxience Research S.L. (1) · AbbVie (1) · Hamad Medical Corporation (1) · AbbVie (prior sponsor, Abbott) (1) · Abbott (1) · Fred Hutchinson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Palivizumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) DiseaseActive, not recruitingNot applicableAstraZenecaNCT06851806Written as Palivizumab 15 mg/kg
- Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSVCompletedPhase 1mAbxience Research S.L.NCT04540627Written as Palivizumab
- Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)CompletedPhase 4MedImmune LLCNCT00233064Written as Lyophilized Palivizumab
- A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of BelarusCompletedPhase 3AbbVieNCT02968173Written as Palivizumab
- "Palivizumab Therapy for RSV-bronchiolitis"CompletedPhase 3Hamad Medical CorporationNCT02442427Written as Palivizumab
- Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical ConditionsCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01466062Written as Palivizumab
- Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) SeasonCompletedPhase 2MedImmune LLCNCT00316264Written as Motavizumab, palivizumab
- Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian ChildrenCompletedPhase 2/3AbbottNCT01006629Written as palivizumab
- A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)CompletedPhase 2MedImmune LLCNCT00240929Written as MEDI-493
- Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell TransplantationCompletedPhase 3Fred Hutchinson Cancer CenterNCT00014391Written as palivizumab
As the comparator · 5 — what is tested is compared with Palivizumab
- Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)CompletedPhase 3Merck Sharp & Dohme LLCNCT04938830Written as Palivizumab
- A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk ChildrenCompletedPhase 2/3AstraZenecaNCT03959488Written as Palivizumab
- Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk ChildrenCompletedPhase 3MedImmune LLCNCT00129766Written as palivizumab
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in ChildrenCompletedPhase 1/2MedImmune LLCNCT00113490Written as palivizumab 15 mg/kg
- A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart DiseaseCompletedPhase 2MedImmune LLCNCT00538785Written as Palivizumab
Codes
What other systems call Palivizumab · ClinicalTrials.gg INT006586
- MeSH (NLM) D000069455PalivizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DQ448MW7KSPALIVIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 194279Confirmed FDA, Wikidata
- Wikidata Q412765palivizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2625PalivizumabOne source FDA
- DrugBank DB00110One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069455 | Palivizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DQ448MW7KS | PALIVIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 194279 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412765 | palivizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2625 | Palivizumab | One source FDA |
| DrugBank | DB00110 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.